Ionis Pharmaceuticals, Inc.
IONS
株式のランク
#2558
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
株価
$45.20
最終同期: 2026-10-20
時価総額
$7.51B
変化（1日）
1.85%
変化（1年）
-36.91%
国
US
取引 Ionis Pharmaceuticals, Inc. (IONS)
カテゴリー
Healthcare
Ionis Pharmaceuticals, Inc.（IONS）の収益
Jun 2026 時点の収益 TTM: $873.76M
Ionis Pharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は $873.76M です。2023 年には $787.65M の収益があり、これは 2022 年の $587.37M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Ionis Pharmaceuticals, Inc. の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $873.76M | 23.91% |
| 2024 | $705.14M | -10.48% |
| 2023 | $787.65M | 34.10% |
| 2022 | $587.37M | -27.53% |
| 2021 | $810.46M | 11.13% |
| 2020 | $729.26M | -35.04% |
| 2019 | $1.12B | 87.20% |
| 2018 | $599.67M | 16.63% |
| 2017 | $514.18M | 37.93% |
| 2016 | $372.78M | 31.40% |
| 2015 | $283.70M | 32.47% |
| 2014 | $214.16M | 45.41% |
| 2013 | $147.29M | 44.33% |
| 2012 | $102.05M | 2.99% |
| 2011 | $99.09M | -8.65% |
| 2010 | $108.47M | -10.80% |
| 2009 | $121.60M | 13.44% |
| 2008 | $107.19M | 83.72% |
| 2007 | $58.34M | 292.65% |
| 2006 | $14.86M | -62.98% |
| 2005 | $40.13M | -5.84% |
| 2004 | $42.62M | -14.73% |
| 2003 | $49.99M | -37.65% |
| 2002 | $80.18M | 50.51% |
| 2001 | $53.27M | 43.00% |
| 2000 | $37.26M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,344.83% |
US
|
|
| $2.23B | 154.99% |
US
|
|
| $15.74B | 1,701.91% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 589.12% |
NL
|
